Even after a cancer drug receives regulatory approval, patients may face barriers to accessing these medications. Issues such as high costs, insurance coverage limitations, and regional disparities in drug availability can restrict patient access. Moreover, some drugs may not be included in national formularies, limiting their distribution in certain regions.
